Integrase inhibitors in the treatment of HIV-1 infection.
about
Microbicides: topical prevention against HIVLocalization of ASV integrase-DNA contacts by site-directed crosslinking and their structural analysisSafety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfilePerformance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations.Role of raltegravir in the management of HIV-1 infection.HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsUncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging studyDolutegravir: first global approval.Urological aspects of HIV and AIDS.Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations.Patterns of resistance development with integrase inhibitors in HIV.Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report.Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.3D-QSAR studies of quinoline ring derivatives as HIV-1 integrase inhibitors.Dolutegravir: a new option for HIV treatment
P2860
Q26999403-3FCCD044-CD82-4E8C-A16D-A687358AF2C2Q28478206-7DB6A131-2AB5-40DD-84B4-B1A7FAEA8646Q34316681-25002389-5730-4E9F-A5B6-4324A5A0ACBEQ34520239-C5528B0D-33DF-4CC1-85CA-2AC861CF3D7CQ34540677-C2D3C3AB-B764-44E6-9941-A3D8EAAA7C62Q35066993-E8B12FF1-AB1B-4AD7-8CD5-C72FC8317886Q35557318-A3F2BC9D-6F90-4BEA-A058-2ADA9A1262CDQ35946584-ECC0A10B-DDB5-4E1E-8B65-DCE84FE84BA3Q36018556-D79E6569-9B3B-4358-9E74-F9F405F50981Q36086711-01009A3C-CAF8-41F5-BEAD-05147B417FE2Q36667054-AB08A386-F560-4498-928A-5423C827812BQ36959425-4F7A6E3F-02B5-4D6D-BE32-4F7C76239E95Q38139885-03E9F963-5B7E-461D-81DF-F099E7AD0CFFQ38156073-EB845966-B80B-4526-9BE8-44620AC5B5AFQ38367106-1825DD3E-D703-40D3-ABD7-ACF3E5C743CCQ41884572-97FB9569-C1E8-4572-9E78-ED464320943EQ42262160-85F68408-2BCA-4552-AAD5-CFB50B85BEB9Q43442926-FE353313-C56F-4F6D-BA6A-6CCB8D56DD25Q45871849-D551791A-D90C-43CF-B9F2-3D48BE4763ECQ54482597-5F14EF2B-1D49-4C9F-B93B-1EE043251C4CQ58290460-934B0B12-F544-4119-9D4D-8AD227491FE1
P2860
Integrase inhibitors in the treatment of HIV-1 infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Integrase inhibitors in the treatment of HIV-1 infection.
@en
Integrase inhibitors in the treatment of HIV-1 infection.
@nl
type
label
Integrase inhibitors in the treatment of HIV-1 infection.
@en
Integrase inhibitors in the treatment of HIV-1 infection.
@nl
prefLabel
Integrase inhibitors in the treatment of HIV-1 infection.
@en
Integrase inhibitors in the treatment of HIV-1 infection.
@nl
P2860
P356
P1476
Integrase inhibitors in the treatment of HIV-1 infection
@en
P2093
William G Powderly
P2860
P304
P356
10.1093/JAC/DKQ350
P407
P577
2010-09-18T00:00:00Z